MX2014013039A - Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple. - Google Patents

Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.

Info

Publication number
MX2014013039A
MX2014013039A MX2014013039A MX2014013039A MX2014013039A MX 2014013039 A MX2014013039 A MX 2014013039A MX 2014013039 A MX2014013039 A MX 2014013039A MX 2014013039 A MX2014013039 A MX 2014013039A MX 2014013039 A MX2014013039 A MX 2014013039A
Authority
MX
Mexico
Prior art keywords
multiple sclerosis
treating
human patient
laquinimod
subject
Prior art date
Application number
MX2014013039A
Other languages
English (en)
Spanish (es)
Inventor
Dan Bar-Zohar
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014013039(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2014013039A publication Critical patent/MX2014013039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2014013039A 2012-05-02 2013-05-01 Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple. MX2014013039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641389P 2012-05-02 2012-05-02
PCT/US2013/039090 WO2013166166A1 (en) 2012-05-02 2013-05-01 Use of high dose laquinimod for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
MX2014013039A true MX2014013039A (es) 2015-02-04

Family

ID=49514859

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013039A MX2014013039A (es) 2012-05-02 2013-05-01 Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.

Country Status (21)

Country Link
US (3) US20130303569A1 (OSRAM)
EP (1) EP2844255A4 (OSRAM)
JP (2) JP2015515985A (OSRAM)
KR (1) KR20150013658A (OSRAM)
CN (2) CN105832733A (OSRAM)
AR (1) AR090885A1 (OSRAM)
AU (1) AU2013256352A1 (OSRAM)
BR (1) BR112014027010A2 (OSRAM)
CA (1) CA2870684A1 (OSRAM)
CL (1) CL2014002935A1 (OSRAM)
EA (1) EA201492010A1 (OSRAM)
HK (1) HK1206246A1 (OSRAM)
IL (1) IL235337A0 (OSRAM)
MX (1) MX2014013039A (OSRAM)
PE (1) PE20150161A1 (OSRAM)
PH (1) PH12014502447A1 (OSRAM)
SG (1) SG11201406594UA (OSRAM)
TW (2) TW201804997A (OSRAM)
UY (1) UY34775A (OSRAM)
WO (1) WO2013166166A1 (OSRAM)
ZA (1) ZA201408820B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
EP2956137A4 (en) * 2013-02-15 2016-08-03 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AR098924A1 (es) * 2013-12-23 2016-06-22 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
UY36099A (es) * 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
WO2017027512A1 (en) * 2015-08-13 2017-02-16 Teva Pharmaceutical Industries Ltd. Use of laquinimod to treat traumatic brain injury
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease
JP7724151B2 (ja) * 2018-07-20 2025-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 多発性硬化症の治療及び予防方法における使用のための置換されたアミノ－ピリミジン化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
PL1797109T3 (pl) * 2004-09-09 2016-11-30 Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
HUE026406T2 (en) * 2009-06-19 2016-06-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
EP2523668A1 (en) * 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
SG11201401330YA (en) * 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
EP2956137A4 (en) * 2013-02-15 2016-08-03 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD

Also Published As

Publication number Publication date
CA2870684A1 (en) 2013-11-07
ZA201408820B (en) 2016-06-29
EP2844255A1 (en) 2015-03-11
TW201804997A (zh) 2018-02-16
HK1206246A1 (en) 2016-01-08
US20160000775A1 (en) 2016-01-07
PE20150161A1 (es) 2015-02-22
TW201347762A (zh) 2013-12-01
JP2015515985A (ja) 2015-06-04
CN104284663A (zh) 2015-01-14
PH12014502447A1 (en) 2015-01-12
EP2844255A4 (en) 2015-10-14
CL2014002935A1 (es) 2015-03-06
AR090885A1 (es) 2014-12-10
UY34775A (es) 2013-11-29
KR20150013658A (ko) 2015-02-05
BR112014027010A2 (pt) 2017-06-27
SG11201406594UA (en) 2014-11-27
CN105832733A (zh) 2016-08-10
AU2013256352A1 (en) 2014-11-27
WO2013166166A1 (en) 2013-11-07
JP2017222691A (ja) 2017-12-21
US20150265592A1 (en) 2015-09-24
IL235337A0 (en) 2014-12-31
US20130303569A1 (en) 2013-11-14
EA201492010A1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PH12014500386A1 (en) Combination treatment for hepatitis c
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
NZ589445A (en) Rasagiline for parkinson's disease modification
NZ714963A (en) Compositions and methods for treating anemia
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
JP2016505050A5 (OSRAM)
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2013003523A (es) Composicion farmaceutica de dosis baja.
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
UA115250C2 (uk) Фармацевтичні комбінації
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
NZ597675A (en) Medicament for the long term nsaid use
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
NZ599227A (en) Therapeutic agent for chronic pain
CY1117605T1 (el) Θεραπεια της ασθενειας crohn me laquinimod